21 years of historical data (2005–2025) · Healthcare · Medical - Care Facilities
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Select Medical Holdings Corporation trades at 14.0x earnings, 50% above its 5-year average of 9.3x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 37%. On a free-cash-flow basis, the stock trades at 5.4x P/FCF, 34% below the 5-year average of 8.1x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.1B | $1.8B | $2.3B | $1.6B | $1.7B | $2.1B | $1.9B | $1.6B | $1.1B | $1.2B | $914M |
| Enterprise Value | $5.7B | $5.5B | $5.0B | $6.0B | $6.7B | $6.7B | $5.9B | $5.8B | $4.2B | $3.8B | $3.6B |
| P/E Ratio → | 14.02 | 12.58 | 11.36 | 6.63 | 10.87 | 5.29 | 7.72 | 8.16 | 7.80 | 10.93 | 8.21 |
| P/S Ratio | 0.38 | 0.34 | 0.45 | 0.23 | 0.26 | 0.33 | 0.35 | 0.30 | 0.21 | 0.28 | 0.21 |
| P/B Ratio | 1.00 | 0.90 | 1.18 | 0.99 | 1.20 | 1.51 | 1.17 | 0.86 | 1.05 | 1.18 | 0.92 |
| P/FCF | 5.36 | 4.79 | 4.35 | 4.42 | 17.64 | 9.34 | 2.19 | 5.68 | 3.30 | 251.23 | 4.94 |
| P/OCF | 5.92 | 5.29 | 4.54 | 2.68 | 5.85 | 5.14 | 1.88 | 3.68 | 2.18 | 5.16 | 2.64 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Select Medical Holdings Corporation's enterprise value stands at 12.1x EBITDA, 24% above its 5-year average of 9.7x. The Healthcare sector median is 14.2x, placing the stock at a 15% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.01 | 0.96 | 0.90 | 1.06 | 1.09 | 1.06 | 1.06 | 0.83 | 0.86 | 0.83 |
| EV / EBITDA | 12.06 | 11.61 | 10.58 | 7.90 | 11.04 | 7.37 | 7.57 | 8.49 | 6.78 | 7.38 | 7.98 |
| EV / EBIT | 17.12 | 14.12 | 16.46 | 10.38 | 15.65 | 8.82 | 12.26 | 12.48 | 9.98 | 10.65 | 11.72 |
| EV / FCF | — | 14.40 | 9.25 | 17.09 | 71.20 | 30.58 | 6.64 | 20.16 | 12.83 | 778.51 | 19.21 |
Margins and return-on-capital ratios measuring operating efficiency
Select Medical Holdings Corporation earns an operating margin of 6.1%. Operating margins have compressed from 8.3% to 6.1% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 7.3% is modest. ROIC of 4.8% represents below-average returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 11.5% | 11.5% | 12.2% | 14.0% | 11.6% | 14.8% | 14.8% | 14.9% | 14.6% | 16.0% | 14.5% |
| Operating Margin | 6.1% | 6.1% | 5.2% | 8.3% | 6.4% | 11.5% | 10.3% | 8.7% | 8.2% | 8.0% | 7.0% |
| Net Profit Margin | 2.7% | 2.7% | 4.1% | 3.7% | 2.5% | 6.5% | 4.7% | 2.7% | 2.7% | 4.0% | 2.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.3% | 7.3% | 12.0% | 16.4% | 11.5% | 26.7% | 14.6% | 10.1% | 13.3% | 17.4% | 11.8% |
| ROA | 2.6% | 2.6% | 3.2% | 3.2% | 2.1% | 5.4% | 3.5% | 2.2% | 2.5% | 3.5% | 2.5% |
| ROIC | 4.8% | 4.8% | 3.8% | 6.7% | 4.8% | 9.2% | 7.3% | 6.9% | 8.1% | 7.4% | 6.4% |
| ROCE | 7.0% | 7.0% | 4.8% | 8.6% | 6.4% | 11.6% | 9.0% | 8.1% | 8.5% | 8.0% | 7.4% |
Solvency and debt-coverage ratios — lower is generally safer
Select Medical Holdings Corporation carries a Debt/EBITDA ratio of 7.8x, which is highly leveraged (143% above the sector average of 3.2x). Net debt stands at $3.7B ($3.7B total debt minus $27M cash). Interest coverage of 3.3x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.82 | 1.82 | 1.35 | 2.87 | 3.71 | 3.49 | 2.72 | 2.37 | 3.20 | 2.59 | 2.75 |
| Debt / EBITDA | 7.80 | 7.80 | 5.73 | 5.93 | 8.47 | 5.20 | 5.82 | 6.58 | 5.32 | 5.23 | 6.15 |
| Net Debt / Equity | — | 1.81 | 1.32 | 2.84 | 3.64 | 3.43 | 2.37 | 2.19 | 3.03 | 2.47 | 2.65 |
| Net Debt / EBITDA | 7.74 | 7.74 | 5.60 | 5.86 | 8.31 | 5.12 | 5.07 | 6.09 | 5.04 | 5.00 | 5.93 |
| Debt / FCF | — | 9.61 | 4.90 | 12.67 | 53.56 | 21.24 | 4.45 | 14.48 | 9.54 | 527.28 | 14.27 |
| Interest Coverage | 3.32 | 3.32 | 2.36 | 2.92 | 2.54 | 5.63 | 3.12 | 2.32 | 2.12 | 2.31 | 1.78 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.04x means Select Medical Holdings Corporation can comfortably meet its short-term obligations, though there is limited excess liquidity.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.04 | 1.04 | 1.04 | 1.01 | 1.10 | 0.90 | 1.11 | 1.33 | 1.41 | 1.52 | 1.41 |
| Quick Ratio | 1.04 | 1.04 | 1.04 | 1.01 | 1.10 | 0.90 | 1.11 | 1.33 | 1.41 | 1.52 | 2.51 |
| Cash Ratio | 0.03 | 0.03 | 0.06 | 0.09 | 0.15 | 0.06 | 0.40 | 0.37 | 0.25 | 0.20 | 0.17 |
| Asset Turnover | — | 0.93 | 0.92 | 0.87 | 0.83 | 0.84 | 0.72 | 0.74 | 0.85 | 0.87 | 0.87 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 57.85 | 57.80 | 39.66 | 54.25 | 52.32 | 59.17 | 51.42 | 50.76 | 56.82 | 48.86 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Select Medical Holdings Corporation returns 6.4% to shareholders annually — split between a 1.5% dividend yield and 4.9% buyback yield. The payout ratio of 21.5% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 7.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.5% | 1.7% | 2.8% | 4.1% | 3.9% | 2.5% | — | — | — | — | — |
| Payout Ratio | 21.5% | 21.5% | 30.2% | 26.2% | 40.6% | 12.6% | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 7.1% | 7.9% | 8.8% | 15.1% | 9.2% | 18.9% | 13.0% | 12.3% | 12.8% | 9.1% | 12.2% |
| FCF Yield | 18.7% | 20.9% | 23.0% | 22.6% | 5.7% | 10.7% | 45.6% | 17.6% | 30.3% | 0.4% | 20.2% |
| Buyback Yield | 4.9% | 5.5% | 1.6% | 0.8% | 11.7% | 3.9% | 0.8% | 2.4% | 0.6% | 0.4% | 0.3% |
| Total Shareholder Yield | 6.4% | 7.2% | 4.4% | 4.9% | 15.6% | 6.3% | 0.8% | 2.4% | 0.6% | 0.4% | 0.3% |
| Shares Outstanding | — | $124M | $125M | $123M | $125M | $130M | $130M | $130M | $130M | $129M | $128M |
Compare SEM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $2B | 14.0 | 12.1 | 5.4 | 11.5% | 6.1% | 7.3% | 4.8% | 7.8 | |
| $9B | 26.3 | 23.5 | 24.2 | 13.7% | 8.6% | 16.9% | 7.0% | 7.7 | |
| $2B | -2.0 | 8.3 | — | 17.6% | 11.7% | -41.4% | 5.9% | 4.6 | |
| $9B | 6.1 | 5.4 | 10.4 | 90.4% | 11.5% | 21.0% | 12.3% | 2.1 | |
| $2B | -23.9 | 10.1 | 9.7 | 23.1% | 11.8% | -2.2% | 4.1% | 7.1 | |
| $84B | 13.2 | 8.6 | 10.9 | 41.5% | 15.8% | — | 19.9% | 3.2 | |
| $15B | 11.1 | 5.9 | 6.0 | 82.3% | 16.1% | 16.1% | 13.2% | 3.1 | |
| $426M | 0.8 | — | 2.0 | 8.7% | -79.4% | — | -70.1% | — | |
| $964M | 44.6 | 13.2 | 15.8 | 20.1% | 10.3% | 2.0% | 5.6% | 4.1 | |
| $90B | 19.6 | 13.2 | 15.8 | 3.6% | 1.6% | — | 254.1% | 1.2 | |
| $52B | 34.4 | 18.8 | 28.2 | 3.7% | 1.0% | — | 3378.7% | 3.0 | |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 21 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SEM stock.
Select Medical Holdings Corporation's current P/E ratio is 14.0x. The historical average is 8.3x. This places it at the 100th percentile of its historical range.
Select Medical Holdings Corporation's current EV/EBITDA is 12.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 7.8x.
Select Medical Holdings Corporation's return on equity (ROE) is 7.3%. The historical average is 14.6%.
Based on historical data, Select Medical Holdings Corporation is trading at a P/E of 14.0x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Select Medical Holdings Corporation's current dividend yield is 1.54% with a payout ratio of 21.5%.
Select Medical Holdings Corporation has 11.5% gross margin and 6.1% operating margin.
Select Medical Holdings Corporation's Debt/EBITDA ratio is 7.8x, indicating high leverage. A ratio above 4x may signal elevated financial risk.